## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION NUMBER:

10/597,808

FILING DATE:

08/08/2006

FIRST NAMED INVENTOR:

Quanlai Song

ART UNIT:

1623

EXAMINER NAME:

To Be Determined

CONFIRMATION NUMBER:

6589

ATTORNEY DOCKET NUMBER: TITLE:

DVCM0002USA

\_\_\_\_

SUBSTITUTED PIXYL PROTECTING

GROUPS FOR OLIGONUCLEOTIDE

SYNTHESIS

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT Under 37 C.F.R. §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 C.F. R. §§ 1.56 and 1.97-98, enclosed herewith are PTO Forms PTO/SB/08A and PTO/SB/08B listing references for consideration by the Examiner.

This application was filed after June 30, 2003. Therefore, pursuant to the waiver of the requirements under 37 C.F.R. § 1.98(a)(2)(i), copies of each U.S. Patent and each U.S. Patent Application Publication are not required to be submitted. Copies of any foreign patent documents and non-patent literature cited herein are enclosed.

This Information Disclosure Statement is being filed before the mailing date of a first office action on the merits. Applicant submits that no fee is required for the consideration of this Information Disclosure Statement. However, if a fee is due, the

Serial No.: 10/597,808 Docket No.: DVCM0002USA

Commissioner is hereby authorized to charge Deposit Account No 500252 referencing case number DVCM0002USA.

\_\_\_\_\_ Dated: 5/31/2007

Respectfully submitted,

Carman K Robinson

Registration No.: 59,489 Isis Pharmaceuticals, Inc. 1896 Rutherford Road

Carlsbad, CA 92008

PTO/SB/08A (04-07)

Approved for use through 09/30/2007. OMB 0651-0001

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information, unless incompany a useful OMB control of the collection of information unless in control or useful OMB control or useful or useful

Substitute for form 1449/PTO			Complete if Known		
			Application Number	10/597,808	
		DISCLOSURE	Filing Date	08/08/2006	
STAT	STATEMENT BY APPLICANT		First Named Inventor	Quanlai Song	
			Art Unit	1623	
(Use as many sheets as necessary)		Examiner Name	To Be Determined		
Sheet	1	of 2	Attorney Docket Number	DVCM0002USA	

	U.S. PATENT DOCUMENTS								
Examiner	Cite	Document Number	Publication Date	Neme of Petentee or Applicant of	Pages, Columns, Lines, Where Relevan				
Initials *	Cite No.1	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear				
	AA	US-5,436,331	07-25-1995	Reese					
	AB	US-5,625,046	04-29-1997	Reese					
	AC	US-2004/0242897	12-02-2004	Guzaev et al.					
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-			<del></del>				
		US-							
		US-							
	<b>—</b>	US-							
		US-							
		US-							
	_	US-							

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	_		
Initials*	No.1	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>		
1	AD	EP 0 617 046 A1	09-28-1994	Nippon Chemiphar				
	AE	EP 0 624 372 A2	11-17-1994	Nippon Chemiphar				
	AF	WO 2004/011474 A1	02-05-2004	Isis Pharmaceuticals				
	$\vdash$							

Examiner Signature	Date Considered	

Cystalore — Considered, whether or not distion is in conformance with MPEP 630. Draw line through claster if not in conformance and not considered, include copy of the form with not communication to applicant. Applicant's urise clasters designation number (optional). \*See Kind Codes of USPTO Patient Concurrent as the Constitution of the Code of USPTO Patient Code of USPTO

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO				Complete if Known			
	INFO	DAGATION	DIE	CLOSURE	Application Number	10/597,808	
					Filing Date	08/08/2006	
	SIAI	EMENIB	YΑ	PPLICANT	First Named Inventor	Quanlai Song	
					Art Unit	1623	
		(Use as many she	ets as	necessary)	Examiner Name	To Be Determined	
	Sheet	2	of	2	Attorney Docket Number	DVCM0002USA	7

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	AG	COLEMAN, M. P. et al., "The S-pixyl group: an efficient photocleavable protecting group for the 5' hydroxyl function of deoxyribonucleosides," <i>Tetrahedron Letters</i> (1999) 40:7911-7915.	
	AH	GAFFNEY, P. R. J. et al., "Some Substituted 9-Phenylzanthen-9-yl Protecting Groups," J. Chem. Soc. Perk. Trans. I (1991) 1355-1360.	
	AI	REESE, C. B. et al., "Synthesis of <u>D</u> -myo-Inositol 1,4,5-Trisphosphate," Tetrahedron Letters (1987) 28(20):2309-2312.	

Signature Date Considered			Date Considered	
---------------------------	--	--	--------------------	--

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

<sup>\*</sup>EXAMINEE: Initial in reterence considered, whether or not catation is in conformance with MPLP\* use. Unswin when through catation in not in commission or again of considered. Include copy of this form with next commission to against unique citation designation unique (robinal). \*Applicant's unique citation designation unique (robinal). \*Applicant is to place a check mark her eff. English language Translation is attached.

This collection of information is required by 37 CFR 19.8. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 11.4. This collection is estimated to be 42 Dis misuses. to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.